Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
Sugimoto H, Nakamura M, Yoda H, Hiraoka K, Shinohara K, Sang M, Fujiwara K, Shimozato O, Nagase H, Ozaki T. Sugimoto H, et al. Among authors: yoda h. Cell Death Dis. 2015 Oct 15;6(10):e1914. doi: 10.1038/cddis.2015.242. Cell Death Dis. 2015. PMID: 26469963 Free PMC article. No abstract available.
Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
Sugimoto H, Nakamura M, Yoda H, Hiraoka K, Shinohara K, Sang M, Fujiwara K, Shimozato O, Nagase H, Ozaki T. Sugimoto H, et al. Among authors: yoda h. Cell Death Discov. 2015 Aug 10;1:15010. doi: 10.1038/cddiscovery.2015.10. eCollection 2015. Cell Death Discov. 2015. PMID: 27551445 Free PMC article.
187 results